Telix completes patient enrollment in Phase 3 BiPASS study
Telix Pharmaceuticals Limited announced completion of patient enrollment in its Phase 3 BiPASS study for commercial PSMA-PET1 imaging agents, Illuccix.
MELBOURNE, Australia and INDIANAPOLIS, Sept.
02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of ga…